title: The vasorelaxing effect of resveratrol on abdominal aorta from rats and its underlying mechanisms.
abstract: Evidence has indicated that resveratrol (Res) produces vasorelaxation and may decrease the coronary heart disease mortality. However, several pathways involved in the mechanism of vasorelaxation are still unclear. This study was designed, therefore, to test the probable ion channels or receptors involved in the mechanism. The abdominal aortic rings from the male Sprague-Dawley rats were perfused in the organ chambers filled with Kreb's solution, where the tension of each ring was measured. Treatment with L-NAME (a nitric oxide synthase inhibitor), glibenclamide and tetraethylammonium (TEA) significantly attenuated the vasorelaxing effect of Res. In lower concentration Res relaxed the ring in an endothelium-dependent manner, while in higher concentration the endothelium-independent manner could be observed. In calcium-free Kreb's solution, Res inhibited vasoconstriction induced by NE. With intracellular calcium depleted by thapsigargin, Res also inhibited vasoconstriction induced by Kreb's solution with high potassium via L-Ca(2+) channel. In a word, Res decreased both extracellular calcium influx and intracellular calcium release. These results suggest that: (1) Res may exert its relaxing effect on abdominal aorta by opening K(+) channel to hyperpolarize vascular smooth muscle.(2) Res relaxes the abdominal aorta in both endothelium-dependent and endothelium-independent manners. (3) Finally, Res attenuates both extracellular calcium influx and intracellular calcium release, which results in vasorelaxation.
authors: Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an 710033, China.
authors: Min
authors: M
authors: Shen
authors: Lei
authors: L
authors: Zhao
authors: Rui-xin
authors: RX
authors: Wu
authors: Shu-qiang
authors: SQ
authors: Yue
authors: Jian-ming
authors: JM
authors: Pei
mesh_terms: D000818:Animals; D001012:Aorta, Abdominal / Q000187:drug effects / Q000378:metabolism; D002118:Calcium / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D005905:Glyburide / Q000494:pharmacology; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D019789:Tetraethylammonium / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D015221:Potassium Channels; D013267:Stilbenes; D014665:Vasodilator Agents; D019789:Tetraethylammonium; D000077185:Resveratrol; D005905:Glyburide; D002118:Calcium; D019331:NG-Nitroarginine Methyl Ester